Merck & Co., Inc. (NYSE:MRK) Shares Purchased by RBA Wealth Management LLC

RBA Wealth Management LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 3.1% in the fourth quarter, HoldingsChannel reports. The firm owned 44,453 shares of the company’s stock after acquiring an additional 1,356 shares during the quarter. RBA Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $4,422,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of MRK. Wellington Management Group LLP increased its position in shares of Merck & Co., Inc. by 4.6% in the third quarter. Wellington Management Group LLP now owns 75,809,383 shares of the company’s stock valued at $8,608,914,000 after buying an additional 3,327,404 shares in the last quarter. International Assets Investment Management LLC increased its position in shares of Merck & Co., Inc. by 11,876.3% during the third quarter. International Assets Investment Management LLC now owns 2,971,554 shares of the company’s stock worth $337,450,000 after purchasing an additional 2,946,742 shares in the last quarter. Two Sigma Advisers LP increased its position in shares of Merck & Co., Inc. by 157.9% during the third quarter. Two Sigma Advisers LP now owns 4,264,100 shares of the company’s stock worth $484,231,000 after purchasing an additional 2,610,800 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec increased its position in shares of Merck & Co., Inc. by 68.7% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 5,388,551 shares of the company’s stock worth $611,924,000 after purchasing an additional 2,194,463 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Merck & Co., Inc. by 3.7% during the third quarter. Geode Capital Management LLC now owns 59,155,004 shares of the company’s stock worth $6,696,060,000 after purchasing an additional 2,134,296 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $99.79 on Tuesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. The stock has a fifty day moving average price of $99.83 and a 200 day moving average price of $107.54. The stock has a market cap of $252.42 billion, a PE ratio of 20.92, a P/E/G ratio of 1.20 and a beta of 0.38. Merck & Co., Inc. has a 1 year low of $94.48 and a 1 year high of $134.63.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, April 7th. Shareholders of record on Monday, March 17th will be given a dividend of $0.81 per share. This represents a $3.24 annualized dividend and a yield of 3.25%. The ex-dividend date is Monday, March 17th. Merck & Co., Inc.’s payout ratio is 67.92%.

Merck & Co., Inc. declared that its board has authorized a stock repurchase program on Tuesday, January 28th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 4.1% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MRK. Truist Financial restated a “hold” rating and issued a $110.00 target price (down from $130.00) on shares of Merck & Co., Inc. in a report on Wednesday, January 8th. Citigroup decreased their target price on Merck & Co., Inc. from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Daiwa America lowered Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 11th. Morgan Stanley dropped their price objective on Merck & Co., Inc. from $123.00 to $113.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 21st. Finally, Bank of America reiterated a “buy” rating and issued a $121.00 price objective on shares of Merck & Co., Inc. in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $122.67.

Check Out Our Latest Research Report on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.